Study to Evaluate Safety and Tolerability of Simultaneous Implant of Spinal Fusion and Neuromodulation Devices in Chronic Lower Back Pain Patients
MINNEAPOLIS , July 26, 2022 /PRNewswire/ -- Justin Zenanko , CEO of SynerFuse, Inc., a Minneapolis -based medical device company, is pleased to announce completion last week of the company's groundbreaking procedure in a fifth patient in the company's proof-of-concept study. The patients have been implanted by Michael C. Park , MD, PhD, and Rohan Lall , MD, at M Health Fairview University of Minnesota Medical Center. (See photo taken after the fifth surgery, left to right: Park, Lall, Zenanko, and SynerFuse Co-Founder and Chief Scientific Officer Greg Molnar , Ph.D.).
The implantation of the fifth patient in our proof-of-concept study is an important milestone for SynerFuse.
"The implantation of the fifth patient in our proof-of-concept study is an important milestone for SynerFuse," said Zenanko. "Now that we have implanted five patients, the Data Safety Monitoring Board will be assembled to review the safety of the SynerFuse therapy concept. We're one step closer to demonstrating the viability of our non-narcotic solution for spinal fusion patients with chronic lower back pain."
The SynerFuse proof-of-concept study involves combining spinal fusion with the implant of a neurostimulator to provide stimulation of the dorsal root ganglion (DRG), a key nerve structure along the spine that can be targeted with neuromodulation to treat chronic neuropathic pain, to provide relief to patients suffering from chronic lower back pain (cLBP). Patients undergoing an initial spinal fusion, among other criteria, are eligible for the study. The proof-of-concept study supports the enrollment of up to 20 patients.
"Bringing this patient-focused therapy from concept to the fifth implant milestone is a true testament to collaboration within our company and with our surgeon and staff partners at the University of Minnesota Medical School and M Health Fairview University of Minnesota Medical Center," said Molnar.
About Chronic Lower Back Pain (cLBP)
cLBP is defined as lower back pain that continues for 12 weeks or longer, even after an initial injury or underlying cause of acute lower back pain has been treated. With 500,000 procedures performed annually, spinal fusion remains a common treatment for spinal instability, albeit with a high incidence of residual neuropathic pain. The continuum of increasingly ineffective opioid treatments, additional interventions, and adjacent level spinal fusions leaves up to 40% of patients with Failed Back Surgery Syndrome (FBSS), a condition resulting in significant, lingering neuropathic pain, costing the U.S. healthcare system $20B per year and significantly affecting the quality of life of patients.
SynerFuse is a Delaware corporation based in Minnesota—the heart of Medical Alley and the cradle of neuromodulation and medical device innovation. SynerFuse believes that individuals with cLBP/FBSS and their providers deserve a better option than spinal fusion alone. Even when spinal fusion is successful, it can often result in residual chronic neuropathic pain and use of addictive opioids. The company is working to create a new future of non-narcotic pain management for chronic low back pain with a patented therapy that integrates spinal fusion hardware and an active neuromodulation system. For more information on the company, please visit www.synerfuse.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/synerfuse-announces-fifth-patient-implanted-in-integrated-spinal-fusion-and-drg-neuromodulation-proof-of-concept-study-301593286.html
SIGA Technologies, maker of the only available monkeypox treatment, is working to ramp up manufacturing for broader global distribution.
We just can't get a break from COVID. While things were inching closer towards normalcy, cases are rising again thanks to the latest dominant variant BA.5, which experts say is the most contagious COVID strain yet. Although the virus affects everyone differently, there are symptoms to watch out for that indicate you've had COVID and Eat This, Not That! Health spoke with Dr. Mark Fischer, Regional Medical Director at International SOS who explains what to know about BA.5 and symptoms to watch out
Whether you're nursing a cold or need a quick and easy lunch, soup is the one food that practically everyone has in their pantry. No matter much or little you know about cooking, being able to grab your can opener or tear into a packet for a reliably good meal is a convenience that's too good for most to pass up—especially if you haven't had time to make it to the grocery store for fresh ingredients lately. But now, the Food&Drug Administration (FDA) is warning consumers that one soup that may b
A Copenhagen company worked for nearly two decades to develop a vaccine and only six governments bought it. Bavarian Nordic A/S is the world’s sole supplier of a licensed vaccine for monkeypox. The World Health Organization in recent days declared the disease a public health emergency of international concern, the first time the group has issued that designation since the early days of the Covid-19 pandemic.
'We need vaccines with longer duration and greater breadth of protection,' said Dr. David Kessler, chief science officer for the White House’s COVID-19 response team.
The highly contagious BA.5 subvariant is causing a nationwide spike in cases, and experts believe the numbers might actually be higher thanks to at-home testing. But even without accurate data, there is no doubt a surge is happening. "You don't have to count every raindrop to know it's raining," says Dr. Joseph Kanter, Louisiana's state health officer and medical director. "And it's pouring right now." Here are five signs of BA.5 that are easy to miss, according to experts. Read on—and to ensure
The Biden administration said it would spend $1.74 billion to buy 66 million doses of Moderna updated Covid-19 vaccine, as well as the option to purchase up to 234 million additional doses, as part of a fall booster campaign. The deal Friday, which follows an agreement to buy 105 million doses of updated vaccines from Pfizer and partner BioNTech SE is expected to give the federal government enough shots for a booster push as early as September. Under the latest deal, the U.S. government has the option to buy up to an additional 234 million doses from Moderna.
We all know the feeling—standing there in the bread aisle at the grocery store, craving a delicious sandwich or slice of toast, while simultaneously telling ourselves that we can't buy any bread because it's "unhealthy."But why do we so often force ourselves to avoid bread when in reality bread isn't the enemy? We've been told for so long that in order to be healthy we have to avoid carbs, but giving up bread completely may mean you'll lose out on valuable nutrients.The main distinction to note
A federal court ruling has dealt a blow to Bausch Health by appearing to clear the way for generic competition for the company’s drug Xifaxan. Bausch Health stock (ticker: BHC) plummeted more than 50% Thursday morning on the news, and trading of the shares was halted. In 2020, Bausch Health Ireland and Salix Pharmaceuticals sued Norwich Pharmaceuticals in 2020 for patent infringement, regarding Norwich’s plans to bring a generic version of Xifaxan to market before its patents had expired, according to a Bloomberg Law report.
Monkeypox has spread across multiple countries, including the U.S., where the Centers for Disease Control and Prevention (CDC) has confirmed almost 5,000 cases since May. While reminiscent of the beginning of the COVID-19 pandemic, this viral disease spreads differently. We all remember masking up, wearing gloves, and waiting in line to get into the grocery store in 2020, but will we have to do that again because of this virus?Experts at the CDC and others say monkeypox spreads mostly through cl
The 300 vaccines that were allocated for DeKalb County are already spoken for.
We are in an epidemic of stress right now, and ashwagandha is an adaptogenic that helps our bodies become more resilient to stress, says Robin Foroutan, RDN.
AstraZeneca's Covid-19 antibody drug slashes the risk of new variants emerging, the company said, as Britain faces mounting pressure to follow other Western nations in ordering doses.
U.S. regulators said Friday they are no longer considering authorizing a second COVID-19 booster shot for all adults under 50 this summer, focusing instead on revamped vaccines for the fall that will target the newest viral subvariants. Pfizer and Moderna expect to have updated versions of their shots available as early as September, the Food and Drug Administration said in a statement. The announcement means the U.S. won’t pursue a summer round of boosters using the current vaccines for adults under 50, as some Biden administration officials and outside experts previously suggested.
Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now?
MRK earnings call for the period ending June 30, 2022.
With growing concerns that the monkeypox outbreak could turn into another pandemic, local health offices have been flooded with requests for the monkeypox vaccine. According to the Centers for Disease Control and Prevention, there have been just 330 cases here in Georgia as of July 29.
The BA.5 COVID variant is the dominant strain in the United States and is more resistant to current vaccines. Here’s what to know about when a booster will be available.
The company had said it was in talks with the FDA about seeking early approval, but Wall Street analysts thought the agency would make it wait to apply.
Breaking down the stigma of mental health and minority mental health awareness